Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420821 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 915
- Enrollment target
NCT02420821 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 915 participants.
The verdict
NCT02420821, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 915 participants
- Enrollment target
Study Summary
This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.
Interventions
- DRUG Bevacizumab
- DRUG Sunitinib
- DRUG Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 915 participants |
| Start Date | 2015-05-20 |
| Est. Completion | 2021-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02420821
The ClinicalTrials.gov registry entry for NCT02420821 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 915 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT02420821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02420821 about?
NCT02420821 is a clinical study titled "A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)". This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or ...
What is the current status of trial NCT02420821?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 915 participants. The study started on 2015-05-20. Estimated completion is 2021-12-13.
What interventions are being tested in trial NCT02420821?
The interventions under investigation include: Bevacizumab (DRUG), Sunitinib (DRUG), Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody (DRUG).
Who is sponsoring clinical trial NCT02420821?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.